BackPhio Pharmaceuticals - Warrants (21/12/2021) Overview

Phio Pharmaceuticals - Warrants (21/12/2021) Operating Income

Phio Pharmaceuticals - Warrants (21/12/2021)'s operating income is $-4.8M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

N/A

As of Mar 31, 2026

Annual Operating Income (TTM)

$-4843000.00
34.98% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Phio Pharmaceuticals - Warrants (21/12/2021) (PHIOW) FAQ

As of the most recent data (March 2026), PHIOW shows a operating income of $-4.8M. That compares with $-3.6M in the prior-year period — down 35.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHIOW's operating income is now $-4.8M (was $-3.6M) — a 35.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Phio Pharmaceuticals - Warrants (21/12/2021) is outperforming or lagging.

Tracking PHIOW's operating income over time shows whether Phio Pharmaceuticals - Warrants (21/12/2021) is scaling, shrinking, or reshaping that part of the business. The current reading is $-4.8M That compares with $-3.6M in the prior-year period — down 35.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Phio Pharmaceuticals - Warrants (21/12/2021)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-4.8M) with ownership activity and broader fundamentals.

Phio Pharmaceuticals - Warrants (21/12/2021)'s operating income is $-4.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.